Article Text

Download PDFPDF
EP699 High incidence with comparable survival of gynecologic sarcomas in israeli population; a comparison to national european and USA reports
  1. Y Brudner1,
  2. G Haran1,
  3. A Blecher1,
  4. BG Silverman2,3,
  5. M Hallak1 and
  6. I Bruchim1
  1. 1Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, affiliated with the Technion, Israel Institute of Technology, Hadera
  2. 2Israel National Cancer Registry, Israel Ministry of Health, Ramat Gan
  3. 3Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel


Introduction/Background Survival reports of gynecologic sarcomas are limited and considered poor. The aim of this study is to explore the incidence and outcome of gynecologic sarcomas in different time periods in Israel and to compare to other national reports.

Methodology Records of gynecologic sarcomas diagnosed between 1980–2014 were extracted from the National Israeli Cancer Registry. Sarcomas were characterized with respect to anatomical site, morphology and demographic variables. Age-standardized incidence rates (ASRs) and 1,3,5 and 10-year relative survival rates were calculated for 3 time periods (1980–1994, 1995–2004 and 2005–2014) according to age, stage and years of diagnosis.

Results During this period (1980–2014), 1271 new gynecologic sarcomas were diagnosed in Israel, with incidence slightly increasing between 1980–2004 years up to ASR of 13 per million females. Incidence was highest in women 45–65 years old. The most common histologic diagnosis was leiomyosarcoma (48%) and most common anatomical site was uterus (89%). The ASR for uterine sarcoma is higher in Israel (10.55 per million females) compared to other national USA and European reports (5.8–9.2/per million). The observed survival rates were comparable to previous reports, with no significant difference through the years of diagnosis and between the Jewish and Non-Jewish populations. The 5 years‘ overall survival is significantly worse in elderly patients (>70 yo) compared to younger patients (P<0.001) and in patients with leiomyosarcoma compared to endometrial stromal sarcoma (p<0.001).

Conclusion Israeli statistics is comparable with global statistics regarding histologic and anatomical variations but the incidence in Israel seems higher than in European population.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.